Aeglea BioTherapeutics has announced approval of their clinical trial application for its novel engineered human enzyme designed to treat homocystinuria. “The approval of the CTA for ACN00177 is an important step forward for our Homocystinuria program and for patients who are in need of new treatment options. Given these unprecedented times, our priorities are to minimize the risk of trial participants being exposed to COVID-19 and avoid further overburdening hospital staff. We are closely monitoring the situation with COVID-19. We remain committed to the patients we serve and are continuing our patient identification and administrative activities in support of this trial to ensure we are prepared to dose patients once circumstances permit” said Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer. Read the Media Release here.